Genmab — Januar 2023
-
Analytikeren hos DNB ved sikkert mere end CEO hos Genmab

-
exactly Sukkeralf. the first approval in the later lines will be for a small indication. this has been clear all the time. whether the will make $50mm or $100mm in sales in the first year will be irrelevant compared to sales in later years... and i certainly don't see how that translates into a dkk200+ PT cut lol
-
Buy when others fear.... if you got the cash, that is

-
Erindre også nogle pessimister omkring juni 2022, hvorefter aktien steg 70 %. Tænk sig, hvordan verden er uforudsigelig
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
sådan er det tit:-)